Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4917838 for persistent predominant negative symptoms of schizophrenia
2010-020370-42Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing RO4917838 plus background antipsychotic therapy with Placebo plus background antipsychotic therapy (2 arms). Primary endpoint: PANSS negative symptoms factor score. Started Oct 2010; status: terminated.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-020370-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020370-42.